CJC-1295 + Ipamorelin Dosage and Blend Vial Math

By Evan Marsh, EditorUpdated August 8, 2026Practice-derived protocols and per-compound arithmetic

Neither compound is approved, so no evidence-based dose exists.Everything below describes protocols that circulate among researchers and the arithmetic behind them. The human studies for these compounds measured hormone levels, not outcomes — see the main guide for what that evidence does and does not cover.

The protocols in circulation

Combination	Common per-dose amount	Frequency	Timing
CJC-1295 no-DAC + ipamorelin	100–200 mcg of each	Daily, sometimes 2–3× daily	Before bed; fasted
CJC-1295 with DAC + ipamorelin	1–2 mg CJC weekly; ipamorelin 200–300 mcg daily	CJC 1–2× weekly	Ipamorelin before bed
Pre-mixed 5/5 mg or 10/10 mg vial	One draw delivers both	Daily	Before bed

Which CJC-1295 form you have changes the entire schedule, and vendors often do not make it clear. With DAC, a single dose elevates GH and IGF-I for days, so weekly dosing makes sense. Without DAC — chemically the same thing as modified GRF(1-29) — the half-life is about thirty minutes and the protocol becomes daily. Detail on theCJC-1295 page.

The blend vial trap

This is the reason this page exists. A vial labelled 5/5 mg contains 10 mg of material — 5 mg of CJC-1295 and 5 mg of ipamorelin. If you run the reconstitution math against the 10 mg total, every dose you draw contains half the intended amount of each compound.

Do the arithmetic per compound. With 5/5 mg in 2.5 ml of bacteriostatic water, each millilitre carries 2,000 mcg of each peptide — not 4,000 mcg of a combined substance. Ten units then delivers 200 mcg of each.

Both calculations look reasonable and only one is right. Every draw from a blend delivers both compounds, so the arithmetic has to be done per compound — using 5 mg, not 10.

Blend vial	Water	Per compound	100 mcg each	200 mcg each	300 mcg each	Doses (200 mcg each)
5/5 mg	2 ml	2,500 mcg/ml	4 units	8 units	12 units	25
5/5 mg	2.5 ml	2,000 mcg/ml	5 units	10 units	15 units	25
5/5 mg	3 ml	1,667 mcg/ml	6 units	12 units	18 units	25
10/10 mg	2.5 ml	4,000 mcg/ml	2.5 units	5 units	7.5 units	50
10/10 mg	4 ml	2,500 mcg/ml	4 units	8 units	12 units	50
10/10 mg	5 ml	2,000 mcg/ml	5 units	10 units	15 units	50

The last column is the sanity check: doses per vial depends only on vial size and dose, never on water volume. A 5/5 mg vial yields 25 doses of 200 mcg each regardless of how you dilute it. If your calculation says otherwise, it is wrong.

A practical note on the 10/10 mg rows: at 2.5 ml, a 100 mcg dose is 2.5 units. Half-unit precision on a U-100 syringe is at the edge of what can be read reliably, and a quarter-unit misread there is a 10% dosing error. More water pushes the same dose into a readable range, at the cost of a longer-lived, more dilute vial.

Peptide preset

Peptide in vial (mg)

Bacteriostatic water added (ml)

Desired dose (mcg)

—

Concentration (mcg / ml)

—

Volume to draw (ml)

—

Units on U-100 insulin syringe

—

Doses per vial

Draw to this mark on a 1 ml U-100 insulin syringe

Formula: concentration = peptide (mcg) ÷ water (ml). Volume = dose ÷ concentration. One unit on a U-100 insulin syringe = 0.01 ml. Values are for laboratory reference only.

The timing rationale

Two conventions appear in nearly every protocol, and both have real physiology behind them rather than being folklore:

Fasted window. Growth hormone release is blunted by elevated insulin and blood glucose. Protocols typically specify no food for about two hours before and thirty minutes after.
Before bed. The largest natural GH pulse occurs in early slow-wave sleep; bedtime dosing stacks the induced pulse on top of it.

Both are sound reasoning. Neither has been tested against an alternative schedule on any clinical endpoint, so treat them as well-motivated convention rather than optimised protocol.

What is genuinely unknown

Whether the combination beats either compound alone. Never tested.
The effective dose of either. Human studies measured hormone response, not outcomes, and were not dose-finding studies for this use.
Whether raising IGF-I produces anything. The systematic review of growth hormone in athletes found increased lean body mass without improved strength — a secretagogue inherits that ceiling.
Long-term safety. No human safety database for either compound in this application.

Recommended supplier · affiliate partner

CJC-1295 + Ipamorelin blend — American Peptides

Sold as a pre-mixed blend vial. Check whether the CJC-1295 component is the DAC or no-DAC form — it changes the dosing schedule completely, and listings frequently do not say.

Check Price →

We may earn a commission if you buy through this link (at no extra cost to you). Sold for research purposes only.

Frequently asked questions

What is the standard CJC-1295 and ipamorelin dosage?

No approved dose exists. Protocols in circulation use 100–200 mcg of each compound daily for the no-DAC combination, taken before bed in a fasted window. With the DAC form of CJC-1295 the pattern changes: roughly 1–2 mg of CJC weekly, with ipamorelin dosed daily at 200–300 mcg.

How do you calculate the dose from a 5/5 mg blend vial?

Per compound, never from the total. A 5/5 mg vial holds 10 mg in total but 5 mg of each peptide. Reconstituted with 2.5 ml, each millilitre carries 2,000 mcg of each compound, so 10 units on a U-100 syringe delivers 200 mcg of each. Dosing against the 10 mg total is the single most common error and halves what you intended.

Why are these two combined?

They act on different receptors. CJC-1295 is a GHRH analog that tells the pituitary to release growth hormone; ipamorelin is a selective ghrelin receptor agonist that amplifies the same release through a separate pathway and suppresses somatostatin. The rationale is complementary mechanisms — no trial has tested whether the combination outperforms either alone.

Why take it before bed on an empty stomach?

Both parts have a pharmacological basis. Growth hormone release is blunted by elevated insulin and blood glucose, which is why protocols specify a fasted window — commonly no food for about two hours before and 30 minutes after. Bedtime timing stacks the induced pulse on top of the largest natural GH pulse, which occurs in early slow-wave sleep.

Does the timing or dose split actually matter?

The fasting and bedtime rationale is sound physiology. Whether it produces a measurably different outcome has not been tested — no trial has compared dosing schedules for this combination on any clinical endpoint.

Sources

Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism, 2006;91(3):799–805. PubMed
Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 2006;91(12):4792–7. PubMed
Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998;139(5):552–61. PubMed
Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews, 2018;6(1):45–53. PubMed
Liu H et al. Systematic review: the effects of growth hormone on athletic performance. Annals of Internal Medicine, 2008;148(10):747–58. PubMed
World Anti-Doping Agency. Prohibited List 2026, section S2.2 — names CJC-1295 and ipamorelin. WADA Prohibited List

Related guides

Research use only. Neither compound is approved for human use. This page describes circulating protocols and the arithmetic behind them; it is not medical advice.